Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised controlled trial
Rowbotham, Sophie E., Cavaye, Doug, Jaeggi, Rene, Jenkins, Jason S., Moran, Corey S., Moxon, Joseph V., Pinchbeck, Jenna L., Quigley, Frank, Reid, Christopher M., and Golledge, Jonathan (2017) Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised controlled trial. Trials, 18 (1). pp. 1-8.
|
PDF (Published Version)
- Published Version
Available under License Creative Commons Attribution. Download (657kB) | Preview |
Abstract
Background: Abdominal aortic aneurysm (AAA) is a slowly progressive destructive process of the main abdominal artery. Experimental studies indicate that fibrates exert beneficial effects on AAAs by mechanisms involving both serum lipid modification and favourable changes to the AAA wall.
Methods/design: Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME) is a multicentre, randomised, double-blind, placebo-controlled clinical trial to assess the effect of orally administered therapy with fenofibrate on key pathological markers of AAA in patients undergoing open AAA repair. A total of 42 participants scheduled for an elective open AAA repair will be randomly assigned to either 145 mg of fenofibrate per day or identical placebo for a minimum period of 2 weeks prior to surgery. Primary outcome measures will be macrophage number and osteopontin (OPN) concentration within the AAA wall as well as serum concentrations of OPN. Secondary outcome measures will include levels of matrix metalloproteinases and proinflammatory cytokines within the AAA wall, periaortic fat and intramural thrombus and circulating concentrations of AAA biomarkers.
Discussion: At present, there is no recognised medical therapy to limit AAA progression. The FAME trial aims to assess the ability of fenofibrate to alter tissue markers of AAA pathology.
| Item ID: | 48090 |
|---|---|
| Item Type: | Article (Research - C1) |
| ISSN: | 1745-6215 |
| Keywords: | abdominal aortic aneurysm, fenofibrate, clinical trial, osteopontin, macrophage |
| Additional Information: | © The Author(s). 2017. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| Funders: | National Medical and Health Research Council (NHMRC), Queensland Government |
| Projects and Grants: | NHMRC 1020955, 1000967, 1019921 & 045862 |
| Date Deposited: | 29 Mar 2017 01:39 |
| FoR Codes: | 32 BIOMEDICAL AND CLINICAL SCIENCES > 3201 Cardiovascular medicine and haematology > 320101 Cardiology (incl. cardiovascular diseases) @ 100% |
| SEO Codes: | 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920103 Cardiovascular System and Diseases @ 100% |
| Downloads: |
Total: 992 Last 12 Months: 6 |
| More Statistics |
Actions (Repository Staff Only)
 |
Item Control Page |